Human C4.4A/LYPD3 Antibody Summary
Leu31-His286
Accession # O95274
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of Human C4.4A/LYPD3 by Western Blot. Western blot shows lysates of SK‑BR‑3 human breast cancer cell line, MCF‑7 human breast cancer cell line, and RT-4 human bladder carcinoma cell line. PVDF membrane was probed with 0.5 µg/mL of Sheep Anti-Human C4.4A/LYPD3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5428) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (HAF016). A specific band was detected for C4.4A/LYPD3 at approximately 75 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: C4.4A/LYPD3
LYPD3 (Ly6/PLAUR-domain containing protein 3; also MIG-C4 and GPI anchored metastasis-associated protein C4.4A) is an 85‑95 kDa, variably glycosylated member of the Ly6 family of GPI anchored proteins. It is expressed on transitional epithelium, keratinocytes and monocytes, and binds laminin 1 and 5, plus Galectin‑3. LYPD3 is believed to support cell migration. Mature human LYPD3 is a 296 amino acid (aa) GPI linked glycoprotein. It contains two UPAR domains
(aa 33‑126 and 140‑222), and an ADAM cleavage site (aa 312‑325). The molecule shows extensive N and O linked glycosylation. There is one potential isoform that shows a deletion of aa 129‑180. Over aa 31‑286, human LYPD3 shares 81% aa identity with mouse LYPD3.
Product Datasheets
Citations for Human C4.4A/LYPD3 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
3
Citations: Showing 1 - 3
Filter your results:
Filter by:
-
New Blocking Antibodies against Novel AGR2–C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice
Authors: Thiruvengadam Arumugam, Defeng Deng, Laura Bover, Huamin Wang, Craig D. Logsdon, Vijaya Ramachandran
Molecular Cancer Therapeutics
-
De novo synthesis of C4.4A in hepatocellular carcinoma promotes migration and invasion of tumor cells
Authors: M Görtz, U Galli, T Longerich, M Zöller, U Erb, P Schemmer
Oncol. Rep., 2017-09-20;38(5):2697-2704.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer
Authors: KJ Cocce, JS Jasper, TK Desautels, L Everett, S Wardell, T Westerling, R Baldi, TM Wright, K Tavares, A Yllanes, Y Bae, JT Blitzer, C Logsdon, DP Rakiec, DA Ruddy, T Jiang, G Broadwater, T Hyslop, A Hall, M Laine, L Phung, GL Greene, LA Martin, S Pancholi, M Dowsett, S Detre, JR Marks, GE Crawford, M Brown, JD Norris, CY Chang, DP McDonnell
Cell Rep, 2019-10-22;29(4):889-903.e10.
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human C4.4A/LYPD3 Antibody
There are currently no reviews for this product. Be the first to review Human C4.4A/LYPD3 Antibody and earn rewards!
Have you used Human C4.4A/LYPD3 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
